Qurin
Qurin is a Dutch pre-revenue diagnostic biotech developing a patented urine-based liquid biopsy platform for early cancer detection, with its initial clinical focus on bladder cancer and a roadmap into multi-cancer screening via the ARPA-H POSEIDON program.
- Company typePrivate
- Founded2017
- HeadquartersLeiden, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Qurin does
Qurin Holding B.V. is a Dutch diagnostic biotechnology company headquartered at the Leiden Bio Science Park, with a registered office in Amsterdam. It is developing a non-invasive, urine-based liquid biopsy platform that uses patented sample collection and biomarker pre-concentration technology to amplify cell-free DNA signals for early cancer detection. The company's workflow integrates with widely accessible laboratory tools such as PCR and is positioned as orthogonal and complementary to existing liquid-biopsy approaches, focusing on the upstream sample-handling step that determines signal quality.
The platform's initial clinical focus is bladder cancer detection from urine, with a stated roadmap to expand into a broader pipeline of oncology diagnostics targeting cancers where early detection has the largest clinical and economic impact. The technology is also being applied beyond oncology to other molecular diagnostic applications through research collaborations. Qurin's core technical claims—10× easier to perform, 10× more biomarkers, and 10× easier to process in the lab—relate to the upstream sample collection and pre-concentration step rather than downstream analytics. The company employs roughly 15 people spanning biomarker discovery, molecular chemistry, IVD development, clinical research, R&D engineering, machine learning, and business strategy, supported by a board including a former Antwerp University Hospital CEO and seasoned finance and nanotechnology advisors.
Qurin is currently pre-revenue and pre-commercialization: the website notes a product "coming soon," no pricing is publicly disclosed, and the only disclosed monetary inflow is a USD 2.3 million subcontract with Owlstone Medical under the U.S. ARPA-H POSEIDON multi-cancer screening program, alongside partners MIT, Boston University, Georgia Tech Research Corporation, and Planned Systems International. Future revenue is intended to come from the sale of diagnostic tests once products launch, with potential secondary revenue from research partnerships and broader non-oncology diagnostic applications.
Qurin firmographics
Firmographics- Name
- Qurin
- Legal name
- Qurin Holding B.V.
- Website
- https://qurin.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Qurin is a Dutch pre-revenue diagnostic biotech developing a patented urine-based liquid biopsy platform for early cancer detection, with its initial clinical focus on bladder cancer and a roadmap into multi-cancer screening via the ARPA-H POSEIDON program.
- Ownership category
- akta.pro rank
Qurin industry classification
Industry- Product category
- Urine-based cancer diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)
Keywords
Where Qurin is headquartered
LocationHeadquarters
- HQ city
- Leiden
- HQ country
- Netherlands
- HQ region
- Europe
Offices2 records
Markets served
Qurin business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Diagnostic Tests and Services: Qurin is a pioneering diagnostic biotech company. The company's initial focus is on validating their platform for early detection of bladder cancer from urine while growing their pipeline of potential applications. Revenue will be generated through sale of diagnostic tests once products are commercialized.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Qurin product offering
Product offeringCore offering
Qurin develops a non-invasive, patented urine-based sample collection and biomarker extraction platform for early cancer detection. The technology captures cell-free DNA from large urine volumes collected at home or at point-of-care, amplifying cancer signals to improve diagnostic accuracy. The initial clinical focus is on bladder cancer detection, with a pipeline targeting additional oncology indications where early detection offers the greatest clinical and economic impact.
Product overview
Qurin offers a urine-based diagnostic platform for early cancer detection. The core offering consists of a patented sample collection and biomarker extraction technology that amplifies cancer signals from urine samples. Their proprietary cell-free DNA capture technology enables DNA extraction from large urine volumes collected at home or point-of-care settings, yielding high DNA concentrations for enhanced molecular analysis. The platform is initially focused on bladder cancer detection while building a pipeline for other oncology applications. The urine-based platform is designed to make cancer testing significantly easier to perform, yield more biomarkers, and be easier to process in laboratory settings.
Differentiator
Problem solved
Functional benefit
Products and services
- Urine-Based Cancer Detection Platform A non-invasive, patented sample collection and biomarker extraction platform that amplifies cancer signals from urine for improved early cancer detection. Designed to make cancer testing 10x easier to perform, yield 10x more biomarkers, and be 10x easier to process in the laboratory. Targets healthcare providers, hospitals, and clinical laboratories seeking early cancer detection solutions, with bladder cancer as the initial proof-of-concept indication.
- Cell-Free DNA Capture Technology A proprietary DNA extraction method enabling DNA extraction from large urine volumes collected either at home or in point-of-care settings, yielding high concentrations of DNA for enhanced molecular analysis. Developed for the ARPA-H POSEIDON program targeting multi-cancer early detection (MCED) tests screening for 30+ cancers at Stage 1.
Quantifiable outcome
- 10x improvement in biomarker yield and ease of processing
- +3 more outcomes
Companies that use Qurin
Customer profileSegments3 records
Ideal customer profiles2 records
Qurin technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Qurin partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and major.
- Owlstone MedicalcoreQurin signed a USD 2.3 million subcontract with Owlstone Medical as part of ARPA-H's prestigious POSEIDON Cancer Screening Program. Qurin's role is to develop a patient-facing urine collection device along with a corresponding method for synthetic DNA extraction. The partnership leverages Qurin's urine-based diagnostics complementing Owlstone Medical's pioneering Breath Biopsy work for early cancer detection.
- MITmajorPartner in the ARPA-H POSEIDON program led by Owlstone Medical, focusing on developing first-in-class, over-the-counter, Multi-Cancer Early Detection (MCED) tests that screen for 30+ cancers at Stage 1.
- Boston UniversitymajorPartner in the ARPA-H POSEIDON program led by Owlstone Medical, contributing to the development of multi-cancer early detection technologies.
- Georgia Tech Research CorporationmajorPartner in the ARPA-H POSEIDON program led by Owlstone Medical, contributing to the development of multi-cancer early detection technologies.
- Planned Systems International, Inc.majorPartner in the ARPA-H POSEIDON program led by Owlstone Medical, contributing to the development of multi-cancer early detection technologies.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Qurin competitors and assessment
Company assessmentDirect peers
- Pacific Edge Diagnostics: Pacific Edge commercializes Cxbladder, a urine-based bladder cancer detection test. Direct overlap with Qurin's lead bladder-cancer indication and the most natural head-to-head competitor on sample type, indication, and clinician channel.
- Nucleix: Nucleix develops urine-based epigenetic liquid-biopsy assays for lung and bladder cancer. Closely mirrors Qurin's urine-first, methylation-based biomarker strategy for early cancer detection.
- Owlstone Medical: Direct partner in the ARPA-H POSEIDON program. Owlstone operates in non-invasive cancer detection via Breath Biopsy, sharing Qurin's vision of early-stage, patient-friendly cancer screening; both target the same multi-cancer detection space with complementary (breath vs. urine) sample modalities.
- GRAIL: GRAIL's Galleri test is the leading blood-based multi-cancer early detection (MCED) product. Qurin's urine-based platform targets the same Stage 1 solid-tumor screening use case from a different sample type, making GRAIL the most direct head-to-head and partnership candidate.
Emerging players
- VolitionRx: VolitionRx develops Nu.Q blood-based epigenomic cancer diagnostics. Comparable as a small-cap, multi-cancer detection platform with similar stage, capital profile, and commercialization challenges.
- Freenome: Freenome is a closely comparable multi-cancer blood-based screening peer with similar stage and clinical-trial profile. Competes for the same MCED opportunity and partnership attention from pharma and academic collaborators.
Broad incumbents
- Exact Sciences: Owner of Cologuard (CRC screening) and acquirer of Thrive Earlier Detection (MCED). Exact Sciences is the most entrenched commercial cancer-screening franchise and an obvious acquirer or partner for any emerging urine-based MCED platform.
- Personalis: Personalis provides tumor-informed molecular diagnostics including NeXT Personal (MRD). Comparable in molecular assay infrastructure and oncology-focused commercialization, with deeper clinical and biopharma channel footprint.
- Natera: Natera operates Signatera (tumor-informed MRD) and broader molecular residual disease/cancer-detection assays. Overlaps with Qurin in molecular oncology testing infrastructure and payer engagement, though focused on blood-based MRD.
- Guardant Health: Blood-based liquid biopsy leader with Guardant360 and Reveal MRD products. Comparable in pursuing non-invasive oncology detection, with substantially deeper clinical evidence and commercial infrastructure that defines the bar Qurin must meet.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Qurin social profiles
Digital presenceQurin financial estimates
Financial estimateRevenue estimate
Valuation estimate
Qurin leadership team
Management profileNumber of profiles
Profiles7 records
Qurin funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Qurin M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Qurin
What does Qurin do?
Qurin develops a non-invasive, patented urine-based sample collection and biomarker extraction platform for early cancer detection. The technology captures cell-free DNA from large urine volumes collected at home or at point-of-care, amplifying cancer signals to improve diagnostic accuracy. The initial clinical focus is on bladder cancer detection, with a pipeline targeting additional oncology indications where early detection offers the greatest clinical and economic impact.
Is Qurin a public or private company?
Qurin is a private company. It is classified as unknown and is currently operating.
When was Qurin founded?
Qurin was founded in 2017. It employs 11 to 50 people.
Where is Qurin based?
Qurin is headquartered in Leiden, Netherlands, in the Europe region.
How does Qurin make money?
One revenue line is on record: diagnostic Tests and Services.
Who are Qurin's main competitors?
Direct peers on record are Pacific Edge Diagnostics, Nucleix, Owlstone Medical and GRAIL. Emerging players are VolitionRx and Freenome. Broad incumbents are Exact Sciences, Personalis, Natera and Guardant Health.
Does Qurin have an API?
No public API is recorded for Qurin.
What industry is Qurin in?
Qurin's product category is Urine-based cancer diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.